Company: ZVRA
Filing Date: 2025-05-08
Form Type: DEFA14A
Source: 0001193125-25-115961
Chunk: 8

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-08
Form: DEFA14A
Chunk 8
---
 Tamara A. Favorito Chair of Board since May 2023 Director and Chair of Audit Committee since August 2021 P P P P P John B. Bode Director since April 2023 Nominating and Corporate Governance Committee Chair, Audit Committee P P P Douglas W. Calder Director since April 2023, Compensation Committee P P P P Corey M. Watton Director since April 2023 Audit Committee, Compensation Committee P P P Thomas D. Anderson Director since August 2023 Compensation Committee Chair, Nominating and Corporate Governance Committee P P P P P P Alvin Shih, M.D. Director since January 2024 Compensation Committee, Nominating and Corporate Governance Committee P P P Zevra’s Board Includes Complimentary, Diverse & Purposefully Selected Perspectives

Life Sciences Experience Rare Disease Product Experience Proven track record in advancing rare disease therapies from early development through commercialization Extensive experience driving long-term value creation across Fortune 500 pharmaceutical companies to specialized rare disease companies Your Board has Specialized Life Sciences & Rare Disease Expertise Needed to Unlock Significant Stockholder Value

With more than 30 years of industry experience, Ms. Favorito brings: 20 years of expertise as Chief Financial Officer for multiple publicly-traded life science companies, including Signal Genetics, Inc., Favrille, Inc., and Immunic, Inc. A deep understanding of the Company’s history as the only director on the Board prior to 2023 Extensive experience in corporate management, finance, and life sciences Tamara A. Favorito Board Chair since May 2023 Director and Chair of Audit Committee since August 2021 Our Nominees are Proven Leaders With Commercial, Life Sciences, and Financial Expertise With over 40 years of experience in the biopharmaceutical industry, Dr. Dixon brings: Deep marketing expertise with a successful track record leading various life sciences companies. Previously was Chief Marketing Officer and President of Global Marketing at Bristol-Myers Squibb, and Senior Vice President of Marketing at Merck Extensive experience in overseeing drug development, regulatory affairs, and commercial strategy Additional executive experience at West Pharmaceuticals, Osteotech, and Centocor Wendy L. Dixon, Ph.D. Director since April 2023 and member of Audit Committee

4 Mangless’ Nominees are Not Qualified for Zevra’s Board

Proxy solicitor with no life sciences expertise Completely unqualified to serve as a Zevra director No life sciences industry experience or knowledge Only role as a director of a public